Capital Fund Management (CFM)’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.15M | Sell |
93,000
-20,900
| -18% | -$696K | 0.01% | 1161 |
|
|
2026
Q1 | $3.43M | Sell |
113,900
-19,900
| -15% | -$640K | 0.02% | 1090 |
|
|
2025
Q4 | $4.18M | Sell |
133,800
-10,200
| -7% | -$251K | 0.01% | 1283 |
|
|
2025
Q3 | $2.91M | Sell |
144,000
-256,900
| -64% | -$4.51M | 0.01% | 1578 |
|
|
2025
Q2 | $6.72M | Buy |
400,900
+246,500
| +160% | +$3.98M | 0.02% | 969 |
|
|
2025
Q1 | $2.37M | Sell |
154,400
-62,600
| -29% | -$1.12M | 0.01% | 1347 |
|
|
2024
Q4 | $4.78M | Sell |
217,000
-110,100
| -34% | -$2M | 0.01% | 1106 |
|
|
2024
Q3 | $5.89M | Sell |
327,100
-182,600
| -36% | -$3.2M | 0.02% | 950 |
|
|
2024
Q2 | $8.28M | Buy |
509,700
+134,400
| +36% | +$2.07M | 0.02% | 757 |
|
|
2024
Q1 | $5.3M | Buy |
375,300
+103,800
| +38% | +$1.31M | 0.02% | 1024 |
|
|
2023
Q4 | $2.83M | Buy |
+271,500
| New | +$2.53M | 0.01% | 1363 |
|
|
2019
Q2 | – | Sell |
-322,300
| Closed | -$5.05M | – | 1913 |
|
|
2019
Q1 | $5.05M | Sell |
322,300
-658,800
| -67% | -$11.6M | 0.05% | 495 |
|
|
2018
Q4 | $15.1M | Sell |
981,100
-570,400
| -37% | -$11.7M | 0.13% | 200 |
|
|
2018
Q3 | $33.4M | Buy |
1,551,500
+59,000
| +4% | +$1.37M | 0.18% | 136 |
|
|
2018
Q2 | $36.3M | Buy |
1,492,500
+457,900
| +44% | +$9.34M | 0.19% | 150 |
|
|
2018
Q1 | $17.7M | Sell |
1,034,600
-183,200
| -15% | -$3.58M | 0.11% | 279 |
|
|
2017
Q4 | $23.1M | Buy |
1,217,800
+249,900
| +26% | +$3.76M | 0.13% | 203 |
|
|
2017
Q3 | $17M | Buy |
967,900
+231,600
| +31% | +$5.21M | 0.12% | 211 |
|
|
2017
Q2 | $24.5M | Sell |
736,300
-300,800
| -29% | -$9.31M | 0.2% | 145 |
|
|
2017
Q1 | $33.3M | Buy |
1,037,100
+361,100
| +53% | +$12.3M | 0.28% | 98 |
|
|
2016
Q4 | $24.5M | Buy |
676,000
+632,900
| +1,468% | +$25.3M | 0.21% | 129 |
|
|
2016
Q3 | $1.98M | Buy |
43,100
+33,400
| +344% | +$1.74M | 0.02% | 766 |
|
|
2016
Q2 | $487K | Buy |
+9,700
| New | +$516K | ﹤0.01% | 1185 |
|
|
2016
Q1 | – | Sell |
-105,200
| Closed | -$6.91M | – | 1830 |
|
|
2015
Q4 | $6.91M | Buy |
105,200
+68,500
| +187% | +$4.23M | 0.07% | 366 |
|
|
2015
Q3 | $2.07M | Sell |
36,700
-60,800
| -62% | -$3.94M | 0.02% | 607 |
|
|
2015
Q2 | $5.76M | Buy |
97,500
+46,700
| +92% | +$2.88M | 0.07% | 356 |
|
|
2015
Q1 | $3.17M | Sell |
50,800
-186,200
| -79% | -$10.8M | 0.04% | 464 |
|
|
2014
Q4 | $13.6M | Sell |
237,000
-20,900
| -8% | -$1.16M | 0.16% | 164 |
|
|
2014
Q3 | $13.9M | Sell |
257,900
-168,800
| -40% | -$8.94M | 0.16% | 153 |
|
|
2014
Q2 | $22.4M | Sell |
426,700
-45,100
| -10% | -$2.31M | 0.24% | 105 |
|
|
2014
Q1 | $24.9M | Buy |
471,800
+461,900
| +4,666% | +$21.3M | 0.31% | 53 |
|
|
2013
Q4 | $397K | Sell |
9,900
-17,100
| -63% | -$673K | ﹤0.01% | 1343 |
|
|
2013
Q3 | $1.02M | Buy |
27,000
+3,200
| +13% | +$125K | 0.01% | 867 |
|
|
2013
Q2 | $933K | Buy |
+23,800
| New | +$927K | 0.01% | 820 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Capital Fund Management (CFM)'s TEVA Position: Q3 2025 in Review
Capital Fund Management (CFM) sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2025, closing a stake of 114,656 shares — an estimated $2.01M sold.
Capital Fund Management (CFM) first reported a position in TEVA in Q2 2013 and held it in 25 quarters. The position peaked at $52.3M in Q3 2016. 552 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.
- Capital Fund Management (CFM) reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2025 after selling out during the quarter.
- Capital Fund Management (CFM) sold 114,656 Teva Pharmaceutical Industries Limited shares in Q3 2025, an estimated $2.01M.
- Capital Fund Management (CFM) first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 25 quarters.
- Capital Fund Management (CFM)'s Teva Pharmaceutical Industries Limited position peaked at $52.3M in Q3 2016.
- 552 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2025.
Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.